New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
- Details
- Category: Novartis
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF). The findings further substantiate the beneficial effect of Entresto on heart failure symptoms and patients' quality of life observed in the PARADIGM-HF study and in other real-world cohorts.
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release real-world data (RWD) analyses of outcomes associated with direct oral anticoagulants (DOAC) among non-valvular atrial fibrillation (NVAF) patients using the U.S. Medicare database - the nation's largest insurer handling more than one billion total claims per year(1)
Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and MiNA Therapeutics ("MiNA"), a pioneer in RNA activation therapeutics, have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's small activating RNA ("saRNA") therapeutics platform.
Sanofi, Principia agree to develop multiple sclerosis drug candidate
- Details
- Category: Sanofi
Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling.
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
- Details
- Category: Pfizer
Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B. Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its comparability to the SPK-9001 received by the first 10 participants enrolled in the ongoing trial.
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.
Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and will determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.
More Pharma News ...
- New US study reveals key reasons why millions of people with obesity are not receiving adequate care
- FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
- Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
- Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
- Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
- Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
- BIOCAD enters the European market